GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAREPTA THERAPEUTICS INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex, or cash flow) provided for FY2026, FY2027, or beyond; management explicitly stated they would "not... predict the exact timing or the nature" of Levitas growth trends without longer-term data.

Business-Segment Outlook:

• Duchenne (Exon Skipping): Expects product stickiness to remain high (>90% home-dosed) despite competitive entrants (e.g., Dyn's DYN program) expected next year; aims to retain stable patient base due to 10+ year safety profile and long-term efficacy data; expects to compete for new patients based on established value proposition.
• Levitas (Gene Therapy): Current Q3 patient starts viewed as a "clean baseline"; expects long-term potential for growth as field force gains access to new three-year Embark data, functional data, and imaging data; timeline for growth trajectory contingent on data readouts from Cohort 8.
• Myotonic Dystrophy Type 1 (DM1): Upcoming Phase 1b data (later this year) will focus on DMPK knockdown and splicing correction; goal is to achieve "substantially north" of 20–25% knockdown/correction (targeting >25%) to support registration; targeting robust muscle concentrations up to 8 mg/kg siRNA; aims for biomarker-based or VHAT-based accelerated approval.
• Facioscapulohumeral Dystrophy (FSHD): Single ascending dose data showed ~90% inhibition of Dux4-regulated genes; expects multiple-dose update later this year to show >70% inhibition as an "exceptional result"; anticipates registration studies with potential for accelerated approval, though confirmatory randomized studies will likely be required.
• Huntington's Disease (HD): Proof of biologic activity expected "middle of next year" (approx. May); systemic delivery aims to demonstrate robust knockdown in CSF and crossing of the blood-brain barrier to target deep brain nuclei; aims to establish a compelling case within a reasonably sized Phase 1b expansion.

Market and Competitive Outlook:

• Competitive Landscape (Duchenne): Views current market entrants as limited by their own delivery mechanisms (e.g., bispecific antibodies causing receptor downregulation or anemia ceilings) compared to Serapta's alpha-B-beta-6 peptide ligand which allows higher systemic dosing without dose-limiting toxicity.
• Regulatory Standards: Expects FDA to maintain a standard of randomized controlled data for clinical benefit in Duchenne gene therapy prior to approval; anticipates accelerated approval pathways are viable for HD and FSHD if robust biomarker data (splicing correction, Dux4 knockdown) is demonstrated.
• Market Share: Projects Serapta to maintain a durable business base in Duchenne due to patient adherence, caregiver ease (home dosing), and physician familiarity, even as competitors enter the market.

Macro / Industry Outlook:

• No commentary on broader economic trends, interest rates, FX, tariffs, or regulatory policy changes beyond specific therapeutic area standards.

Strategic Initiatives:

• Pipeline Advancement: Targeting a transformational shift in company valuation by 2027 ("27 is going to be a very transformational year") driven by the maturation of three high-value programs (DM1, FSHD, HD) to registration/enrollment stages.
• Expansion: Plans to pursue "many other programs pre-clinically" and expand presence in neuromuscular and neurologic conditions.
• Capital Strategy: Operating on a self-funding basis using commercial cash flows to drive pipeline advancement, explicitly avoiding the need to raise equity.
• Launch Timeline:
  • Later this year: DM1 and FSHD data readouts.
  • Middle of next year: HD proof of biologic activity.
  • 2027: Potential for approvals or advanced registration status for the three core programs.

Risks and Headwinds to Outlook:

• Clinical Trial Variability: Management cautions against over-indexing on small population changes in functional measures (e.g., VHAT) in early studies; notes that studies are powered for biomarkers (splicing/knockdown) rather than immediate functional endpoints.
• Regulatory Uncertainty: Acknowledges "open questions" regarding specific accelerated approval endpoints for DM1 (VHAT vs. biomarker) and confirms FDA interaction is required for FSHD accelerated approval strategy.
• Timeline Flexibility: HD timeline has been pushed to "middle of next year" pending sufficient data to demonstrate convincing proof of biological activity across dose cohorts.
• Competitive Labeling: Future competitive outcomes depend on the final FDA label for DYN, specifically what claims regarding benefit-risk can be made.

Management Tone on the Future:

• High Confidence: CEO describes the company's position as "unique" and "unheard of" in biotech at this scale, citing a robust commercial foundation funding a promising pipeline.
• Transformational Outlook: Explicitly characterizes the 12-month and 3-year outlook as "transformative," expecting the company to be "very different... in a very favorable way."
• Strategic Hedges: Avoids specific numerical growth predictions for Levitas, citing the need to "see longer-term trends" and data readouts before providing precise timing or nature of growth.
• Differentiation: Strongly emphasizes the superiority of their delivery platform over competitors (Novartis, Alnylam) regarding muscle delivery, nuclear knockdown, and safety profiles.

Miscellaneous:

• Safety Data: Highlights a well-understood safety exposure database for Levitas (1,200+ ambulatory patients, 1,500+ overall) compared to competitors with smaller single-arm study histories.
• Delivery Technology: Emphasizes the unique alpha-B-beta-6 peptide ligand capability to rapidly internalize and recycle, maintaining surface availability for high muscle concentrations without depletion.